FeesSafety
Pluang+

Provable and Brave partner to enable private BAT trading for 130M users via Shield platform.

Protocol Fundamentals
19 Nov 2026, 03:21 WIB
Tokenpost
View Source
Bullish
Provable and Brave partner to enable private BAT trading for 130M users via Shield platform.

Provable, the company behind the Shield confidential trading platform, has partnered with Brave, a privacy-focused browser with over 130 million monthly users, to introduce private trading options starting with BAT token on Shield Swap. This partnership aims to enhance financial privacy by allowing users to trade without exposing transaction details publicly, addressing risks like tracking and theft common on public blockchains. The collaboration builds on both companies' commitment to privacy, leveraging technologies like zero-knowledge proofs, and marks a step toward integrating private trading directly within the Brave browser. A full public launch of Shield Swap is expected later this year.

The partnership between Provable and Brave to enable private BAT token trading offers context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 19, 2026 08:21 WIB: out of 50 major cryptocurrencies, 8 rose and 40 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% at Rp16,297 with a typical hold time of 85 days, and LUNC (Terra Classic) up 9.90% at Rp0.793, with Pluang order activity showing 86% sell and 14% buy, and a typical hold time of 198 days.

More News

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic is set to go public on November 19, raising tens of billions to boost its AI capabilities in bioscience, focusing on lab automation and robotics. Ginkgo Bioworks, a leader in automated biotech labs, collaborates with OpenAI but has no curre...

Market News
Bullish
58 minutes ago
BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing Brands saw a 24% surge in its stock price after reporting a 7% increase in net sales to $692 million for fiscal 2026 Q4, driven by strong demand for its high-protein Premier Protein shakes and new product launches like Sparkling Protein Soda...

Company Fundamentals
Bullish
1 hour ago
Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Freedom Broker analyst Vitaly Kononov lowered Peabody Energy's price target from $30 to $22 per share, citing reduced production outlooks at its key Centurion coal mine and vulnerability in coal prices. Despite the significant cut, he maintained a bu...

Analyst Insights
Bearish
1 hour ago
Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
2 hours ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App